<DOC>
	<DOCNO>NCT02526537</DOCNO>
	<brief_summary>Currently , whether adjuvant therapy apply Stage Ib non-small cell lung cancer ( NSCLC ) patient receive radical resection remain controversial . There still clear evidence postoperative adjuvant chemotherapy treatment improve survival rate patient stage Ib NSCLC . Tyrosine Kinase Inhibitors ( TKIs ) Gefitinib Erlotinib widely accept first-line therapy Epidermal growth factor receptor ( EGFR ) gene mutation late stage NSCLC patient . However effect largely uncertain early stage patient receive surgery . The investigator aim evaluate effect postoperative adjuvant use Gefitinib high risk stage Ib EGFR sensitive mutation NSCLC patient .</brief_summary>
	<brief_title>Gefitinib EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients</brief_title>
	<detailed_description>Currently , whether adjuvant therapy apply Stage Ib non-small cell lung cancer ( NSCLC ) patient receive radical resection remain controversial . CALGB9633 study show patient stage Ib NSCLC receive radical resection , postoperative adjuvant chemotherapy benefit patient , patient high risk ( cancer diameter &gt; 4cm ) benefit . There still clear evidence postoperative adjuvant chemotherapy treatment improve survival rate patient stage Ib NSCLC . The EGFR gene mutation rate 10 % European patient , 30-40 % patient Asian origin . In retrospective observation study 1118 stage I stage III NSCLC patient receive surgery , D'Angelo et al . find risk death patient EGFR sensitive mutation lower without mutation . The author indicate postoperative use TKI EGFR sensitive mutation patient might possible reason . Since mutation rate EGRF gene high Asian patient , compare patient origin , investigator speculate Asian patient might benefit postoperative use TKIs . EGFR gene mutation detection routinely prescribe nowadays lung adenocarcinoma patient receive surgical resection . According NCCN guideline , stage IB patient high risk factor recommend receive adjuvant chemotherapy . For patient tolerate decline chemotherapy , non-specific treatment ( Chinese herbal medicine nonspecific immunomodulators adjuvant anti-cancer treatment 2 year ) recommend , otherwise , TKIs（Gefitinib 250 mg daily 2 year ) also alternative choice cancer EGFR sensitive mutation . Based patient 's choice postoperative adjuvant therapy , patient enrol observation prognosis .</detailed_description>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>1 . Highrisk meet one follow description : 1 ) . Poorly differentiate carcinoma ( include neuroendocrine tumor ) ; 2 ) . Vascular invasion ; 3 ) . Tumor diameter≥4cm 5 ) . Visceral pleura involvement . 2 . Patients pathology confirm Ib stage NSCLC 3 . Patients deletion exon 19 mutation L858R exon 21 EGFR gene 4 . ECOG score 01 5 . Life expectancy 12 week 6 . Absolute neutrophil count ( ANC ) &gt; = 1.75 x 109 / L , platelet &gt; = 100 x 109 / L , hemoglobin equal 9 g / dl 7 . Total bilirubin &lt; = normal value 1.5 time upper limit normal ( ULN ) ; liver metastasis , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &lt; = 2.5 time upper limit normal ( ULN ) 8 . Serum creatinine &lt; =1.25 time upper limit normal value , creatinine clearance rate &gt; 60 ml/min 9. receive informed consent patient his/her legal representative 1 . Patients serious allergy ingredient drug use study 2 . Patients unable comply study plan research program ; 3 . Patients severe systemic disease researcher judge unable complete study ; 4 . Patients severe heart disease , myocardial infarction within 6 month ; 5 . Patients interstitial pneumonia ; 6 . Patients confirm positive pathology cut edge ; 7 . The preoperative chest CT show nodule &gt; = 50 % , show ground glass opacity ; 8 . Patients receive wedge resection ; 9 . Patients use HER2 pathway involve drug erlotinib , gefitinib , cetuximab rituximab , trastuzumab ) 10 . Patients receive chemotherapy systemic antitumor therapy ( monoclonal antibody therapy ) ; 11 . Patients receive radiotherapy ; 12 . Having malignant tumor last 5 year , include cure surgery survive 5 year diseasefree ; 13 . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction , serious arrhythmia , liver , kidney metabolic disease within six month ) . 14 . Patients get effective treatment inflammation , eye infection predispose factor ; 15 . Physical examination laboratory finding evidence reasonable doubt ill use relate drug could affect study ; 16 . Patients serious active infection ; 17 . Patients T790M mutation 20 exon ; 18 . Woman pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gefitinib</keyword>
	<keyword>NSCLC</keyword>
	<keyword>postoperative</keyword>
	<keyword>stage Ib</keyword>
	<keyword>Relapse Free Survival 2 year</keyword>
</DOC>